The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
Methyl tert-butyl ether is a suitable solvent for iridium-catalyzed C-H borylation followed, in the same pot, by palladium-catalyzed Suzuki-Miyaura cross-coupling sequences, giving high yields of biaryls.
A process for the concurrent transfer of both the NHC ligand and the difluoromethyl group from [(SIPr)Ag(CF2H)] to PdX2 (X = Cl, OAc, and OPiv) for the preparation of [(SIPr)Pd(CF2H)X] complexes is described. These complexes were air-stable and easily underwent transmetalation with aryl pinacolboronate/reductive elimination to generate ArCF2H in high yields. Based on this discovery, the first one-pot
Room temperature borylation of arenes and heteroarenes using stoichiometric amounts of pinacolborane catalyzed by iridium complexes in an inert solventElectronic supplementary information (ESI) available: experimental procedures and spectral analyses of products. See http://www.rsc.org/suppdata/cc/b3/b311103b/
作者:Tatsuo Ishiyama、Yusuke Nobuta、John F. Hartwig、Norio Miyaura
DOI:10.1039/b311103b
日期:——
Aromatic C–H borylation of arenes and heteroarenes using stoichiometric amounts of pinacolborane was catalyzed by an iridium complex generated from ½[Ir(OMe)(COD)]2 and 4,4′-di-tert-butyl-2,2′-bipyridine at room temperature in hexane and afforded the corresponding aryl- and heteroarylboronates in high yields with excellent regioselectivities.
urease inhibition, all compounds were found more active than the standard used. The compound N-(6-(p-tolyl)benzo[d]thiazol-2-yl)acetamide was found to be the most active. To understand this urease inhibition, molecular docking studies were performed. The in silico studies showed that these acetamide derivatives bind to the non-metallic active site of the urease enzyme. Structure-activity studies revealed
在 Pd(0) 存在下,使用各种芳基硼频哪醇酯/酸,通过 CC 偶联方法合成了一系列新的 N-(6-芳基苯并[d] 噻唑-2-基)乙酰胺。评估了新合成的化合物的各种生物活性,如抗氧化、溶血、抗菌和脲酶抑制。在生物测定中发现这些化合物具有中等至良好的活性。在筛选的测试生物活性中,这些化合物显示出最显着的脲酶抑制活性。在脲酶抑制中,发现所有化合物都比所用的标准品更具活性。发现化合物 N-(6-(对甲苯基)苯并[d]噻唑-2-基)乙酰胺是最有活性的。为了了解这种脲酶抑制作用,进行了分子对接研究。计算机研究表明,这些乙酰胺衍生物与脲酶的非金属活性位点结合。结构-活性研究表明,化合物与酶的 H 键合对其抑制很重要。